Search Results

Showing results 1-10 of 88 for 'cancer'

  • hockey
    Miracle Drug with Israeli Roots Saves Jewish Hockey Player Hit With Cancer

    The Israel Cancer Research Fund (ICRF), which supports cancer research at Weizmann, shares the story of Jewish hockey player Sam Fields, who was felled by aggressive CML just before turning pro. His life was saved, thanks to Gleevec, for which the Institute's Prof. Eli Canaani helped lay the foundation.

  • Idit Shachar
    Target: Blood Cancers

    Read about Prof. Idit Shachar's search for an improved treatment for chronic lymphocytic leukemia and other blood cancers. She and her team discovered a blocking antibody that showed great promise in killing cancer cells in a clinical trial. Prof. Shachar also addresses the challenges of being a woman (and mom) in science. This is WeizmannViews Issue No. 45.

  • double whammy_Lev
    Double Whammy for Triple-Negative Breast Cancer

    Triple-negative breast cancer is particularly hard to treat because, as its name suggests, it lacks three receptors that usually serve as targets for anti-cancer drugs. Now, Prof. Sima Lev has identified a promising new combination therapy that not only inhibits tumor growth and survival, but gets around the problem of drug-induced resistance.

  • October is National Breast Cancer Awareness Month

    October is National Breast Cancer Awareness Month, and people everywhere are running, walking, and even shopping in support – and, at the Weizmann Institute of Science, investigating, researching, and pursuing creative new ways to attack this still-insidious, too-common disease. Our devoted scientists are developing ways to detect breast cancer early, designing more effective treatments, and better preventing it in the first place. Learn what Weizmann is doing about breast cancer – and how you can help.

  • 2016-09-ACWIS-enews-thumbnail
  • T-cell Therapies for Cancer: From Outsider to Pharmaceutical Darling

    As Britain’s Royal Pharmaceutical Society reports in its Pharmaceutical Journal, researchers working on T-cell therapies for cancer – such as Weizmann’s Prof. Zelig Eshhar – were snubbed for years… until now. This thorough overview of the field’s beginning – including in Prof. Eshhar’s lab – and its future makes clear the importance of T cells.

  • Six Leading Scientists to Receive Prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology

    Prof. Zelig Eshhar, whose basic research led to the creation of cancer-killing T-cells, is one of six scientists to receive a 2016 Novartis Prize for Immunology. Announced and granted by the healthcare and pharma company, the prestigious prizes are “awarded every three years for breakthrough contributions to the fields of basic and clinical immunology.”

  • Best People, Best Science

    The Weizmann Institute’s most important asset is its people. That’s why the Institute is committed to recruiting and nurturing some of the world’s brightest young researchers. Here, six impressive new scientists – Drs. Ronen Eldan, Ofer Firstenberg, Yifat Merbl, Neta Regev-Rudzki, Nir London, and Efi Efrati – share how the Institute is helping them make breakthroughs in areas ranging from malaria to optics.

  • Israel Leads in Prostate Cancer Research

    Reporter Natasha Kirtchuk describes the new prostate cancer treatment developed by the Weizmann Institute’s Profs. Avigdor Scherz and Yoram Salomon, along with an extended team of scientists, researchers, oncologists, urologists, clinicians, technicians, and more. The therapy involves no radiation or chemotherapy, takes just 90 minutes to complete...